Overview

  • Product name
    Anti-SOCS3 antibody [SO1]
    See all SOCS3 primary antibodies
  • Description
    Mouse monoclonal [SO1] to SOCS3
  • Host species
    Mouse
  • Tested applications
    Suitable for: Flow Cyt, WB, ICC/IF, ELISAmore details
  • Species reactivity
    Reacts with: Rat, Human
  • Immunogen

    Full length native protein (purified) (Human).

Properties

Applications

Our Abpromise guarantee covers the use of ab14939 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt Use 1µg for 106 cells.

ab170192 - Mouse monoclonal IgG2b, is suitable for use as an isotype control with this antibody.

 

WB Use at an assay dependent concentration. Predicted molecular weight: 27 kDa.
ICC/IF Use a concentration of 5 µg/ml.
ELISA Use at an assay dependent concentration.

Target

  • Function
    SOCS family proteins form part of a classical negative feedback system that regulates cytokine signal transduction. SOCS3 is involved in negative regulation of cytokines that signal through the JAK/STAT pathway. Inhibits cytokine signal transduction by binding to tyrosine kinase receptors including gp130, LIF, erythropoietin, insulin, IL12, GCSF and leptin receptors. Binding to JAK2 inhibits its kinase activity. Suppresses fetal liver erythropoiesis. Regulates onset and maintenance of allergic responses mediated by T-helper type 2 cells. Regulates IL-6 signaling in vivo (By similarity). Probable substrate recognition component of a SCF-like ECS (Elongin BC-CUL2/5-SOCS-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Seems to recognize IL6ST.
  • Tissue specificity
    Widely expressed with high expression in heart, placenta, skeletal muscle, peripheral blood leukocytes, fetal and adult lung, and fetal liver and kidney. Lower levels in thymus.
  • Pathway
    Protein modification; protein ubiquitination.
  • Involvement in disease
    Note=There is some evidence that SOCS3 may be a susceptibility gene for atopic dermatitis linked to 17q25. SOCS3 messenger RNA is significantly more highly expressed in skin from patients with atopic dermatitis than in skin from healthy controls. Furthermore, a genetic association between atopic dermatitis and a haplotype in the SOCS3 gene has been found in two independent groups of patients.
  • Sequence similarities
    Contains 1 SH2 domain.
    Contains 1 SOCS box domain.
  • Domain
    The ESS and SH2 domains are required for JAK phosphotyrosine binding. Further interaction with the KIR domain is necessary for signal and kinase inhibition.
    The SOCS box domain mediates the interaction with the Elongin BC complex, an adapter module in different E3 ubiquitin ligase complexes.
  • Post-translational
    modifications
    Phosphorylated on tyrosine residues after stimulation by the cytokines, IL-2, EPO or IGF1.
  • Information by UniProt
  • Database links
  • Alternative names
    • ATOD4 antibody
    • CIS 3 antibody
    • CIS-3 antibody
    • CIS3 antibody
    • Cish3 antibody
    • Cytokine induced SH2 protein 3 antibody
    • Cytokine-inducible SH2 protein 3 antibody
    • E2a Pbx1 target gene in fibroblasts 10 antibody
    • EF 10 antibody
    • MGC71791 antibody
    • SOCS 3 antibody
    • SOCS-3 antibody
    • Socs3 antibody
    • SOCS3_HUMAN antibody
    • SSI 3 antibody
    • SSI-3 antibody
    • SSI3 antibody
    • STAT induced STAT inhibitor 3 antibody
    • STAT-induced STAT inhibitor 3 antibody
    • Suppressor of cytokine signaling 3 antibody
    see all

Images

  • ICC/IF image of ab14939 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab14939, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-mouse IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • Overlay histogram showing Jurkat cells stained with ab14939 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab14939, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG2b [PLPV219] (ab91366, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in Jurkat cells fixed with 80% methanol (5 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.

References

This product has been referenced in:
  • Liu W  et al. Relationship of SOCS3 and TGF-ß with IDO expression in early pregnancy chorionic villi and decidua. Exp Ther Med 14:4817-4824 (2017). Read more (PubMed: 29201185) »
  • Neuwirt H  et al. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 14:1007-19 (2007). Read more (PubMed: 18045952) »
See all 2 Publications for this product

Customer reviews and Q&As

1-7 of 7 Abreviews or Q&A

Abcam has not validated the combination of species/application used in this Abreview.
Application
Immunohistochemistry (Frozen sections)
Sample
Mouse Tissue sections (Atherosclerotic Plaque)
Permeabilization
Yes - Triton X (1%)
Specification
Atherosclerotic Plaque
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Fixative
Paraformaldehyde

Tessa Barrett

Verified customer

Submitted Aug 13 2018

Application
Western blot
Sample
Rabbit Tissue lysate - whole (Muscle (gastrocnemius))
Gel Running Conditions
Reduced Denaturing (15)
Loading amount
50 µg
Specification
Muscle (gastrocnemius)
Blocking step
Milk as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 25°C

Abcam user community

Verified customer

Submitted Jan 29 2018

Abcam guarantees this product to work in the species/application used in this Abreview.
Application
Western blot
Sample
Rat Tissue lysate - whole (skin)
Loading amount
15 µg
Specification
skin
Blocking step
Milk as blocking agent for 1 hour(s) and 30 minute(s) · Concentration: 5%

Abcam user community

Verified customer

Submitted Feb 13 2007

Answer

Thank you for your enquiry. I am sorry to hear you are having a problem with ab14939. I would like to suggest the following modifications to your protocol: Thank you for submitting that picture. The data sheet lists 27 kDa as the molecular weight for Western blot, so I would say that the band right below 29 would be the band you are looking for. It looks like there is a lot of non-specific binding then, and so my suggestion would be to try incubating the primary antibody overnight at 4C to increase the specificity. I will also let you know that this antibody has only been tested in human, so we can not guarantee that this antibody will work for mouse samples. Please let me know if this helps and do not hesitate to contact us for further advice.

Read More

Answer

Thank you for getting back in touch with me. As mentioned in my previous email I consider SOCS1 peptide (199-211) (ab23167) suitable as a positive control standard for ab3691 as this is the very peptide sequence that the antibody was raised against. With regards mouse monoclonal [SO1] to SOCS3 (ab14939) we do not have a positive control in our catalogue. However, following a brief "Google" search I can tell you I found an epitope tagged recombinant human form of SOCS3 available at the following link; http://www.axxora.com/socs-related_products-ALX-201-334/opfa.1.1.ALX-201-334.1872.4.1.html I hope this information helps, please do not hesitate to contact us if you need any more advice or information.

Read More

Answer

Thank you for getting back in touch with me. Both SOCS1 antibody (ab3691) Rabbit Polyclonal IgG and SOCS3 antibody [SO1] (ab14939) Mouse Monoclonal IgG2b require secondary antibodies for the detection as neither are directly conjugated with fluorescence. There are compatible secondaries at the bottom of each datasheet (dependent on the application). It may also be useful if you look at our available secondary antibodies by hovering on our product browsed and moving across into mouse or rabbit and then IgG. As you see there are many secondary antibodies available. Whilst they are not advertised as so I think that SOCS1 peptide (199-211) (ab23167) is certainly suitable as a positive control standard for ab3691. Unfortunately ab14939 was raised using full length recombinant protein. Therefore I consider it possible that the antibody will not recognise SOCS3 peptide (213-225)(ab22776) with great efficiency given a possibility that the mixture of immunoglobulins does not target this peptide. I hope this information helps, please do not hesitate to contact us if you need any more advice or information.

Read More

Answer

No, the SOCS3 ab (#14939) has not been tested in human fibroblasts (specifically lung fibroblasts) and no the use of this Ab has not been published. In general, we know it works on adherent cell lines. Yes, you should treat samples with inhibitors before you test SOCS3 using this Ab. The protease inhibitors are necessary as well as extraction procedures for nuclear proteins. I think the authors are about to submit a paper, but they have not done so yet.

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up